Evidence map›Paper›PMID 41809987›Full record

ArticleFrontiers in cellular and infection microbiology2026

CLEC3A-derived peptides exhibit broad-spectrum activity against

Katinka Mies, Gabriele Hermes, Jens Beckers, Matthias Mörgelin, Michaela Simon, Tamara Rügamer, Jonathan Jantsch, Andreas R Klatt, Thomas Streichert, Dzemal Elezagic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katinka MiesInstitute for Clinical Chemistry, Medical Faculty, University of Cologne, Cologne, Germany.
Gabriele HermesInstitute for Clinical Chemistry, Medical Faculty, University of Cologne, Cologne, Germany.
Jens BeckersInstitute for Clinical Chemistry, Medical Faculty, University of Cologne, Cologne, Germany.
Matthias MörgelinColzyx AB , Lund, Sweden.
Michaela SimonInstitute of Laboratory Medicine and Microbiology, St. Marien Hospital, Amberg, Germany.
Tamara RügamerInstitute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Jonathan JantschInstitute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Andreas R KlattInstitute for Clinical Chemistry, Medical Faculty, University of Cologne, Cologne, Germany.
Thomas StreichertInstitute for Clinical Chemistry, Medical Faculty, University of Cologne, Cologne, Germany.
Dzemal ElezagicInstitute for Clinical Chemistry, Medical Faculty, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antimicrobial resistance in bacterial and fungal pathogens poses a major threat to global health, with Methods: In this study, the antibacterial and antifungal efficacy of two CLEC3A-derived peptides, HT-47 and WRK-30, was evaluated in comparison to the reference AMP LL-37 and the drugs amphotericin B and penicillin/streptomycin using viable count assays, biofilm assays, and scanning and transmission electron microscopy. Results: HT-47 and WRK-30 showed antibacterial activity against the ESKAPE pathogens Conclusion: CLEC3A-derived peptides HT-47 and WRK-30 exhibit potent and comparable antibacterial and antifungal activity, highlighting their potential as therapeutic candidates for combating multidrug-resistant pathogens, including

Indexed as

Antifungal AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesCandidaCandida aurisAnti-Bacterial AgentsBiofilmsCandida albicansCell MembraneHistatinsHumansMicrobial Sensitivity TestsMicrobial ViabilityMicroscopy, Electron, TransmissionAnti-Bacterial AgentsAntifungal AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesHistatinsHTN3 protein, humanantimicrobial peptide (AMP)Candida aurisCLEC3AESKAPEfungal biofilm

Identifiers

PMID41809987
PMCPMC12968183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.